Contents

Reviews

Suturing Skills for Medical Students: A Systematic Review. T. EMMANUEL, M. NICOLAIDES, I. THEODOULOU, W. YOONG, N. LYMPEROPOULOS, M. SIDERIS (London, UK) .......................................................... 1

Therapeutic Application of Mesenchymal Stem Cells for Cochlear Regeneration. N. MAHARAJAN, G.W. CHO, C.H. JANG (Gwangju, Republic of Korea) ........................................................................................................ 13

Sensitivity, Specificity and the Diagnostic Accuracy of PET/CT for Axillary Staging in Patients With Stage I-III Cancer: A Systematic Review of The Literature. J. KASEM, U. WAZIR, K. MOKBEL (London, UK; Peshawar, Pakistan) ................................................................................................................ 23

Circulating Tumor Cells, Circulating Tumor DNA and Other Blood-based Prognostic Scores in Pancreatic Ductal Adenocarcinoma – Mini-Review. M. LIBERKO, K. KOLOSTOVA, A. SZABO, R. GURLICH, M. OLIVERIUS, R. SOUMAROVA (Prague, Czech Republic) ........................................................................................................ 31

Aortitis – An Interdisciplinary Challenge. T. SHCHETYSNKA-MARINOVA, K. AMENDT, M. SADICK, M. KEESE, M. SIGL (Mannheim, Germany) ........................................................................................................ 41

The Role of Nutritional Support in Malnourished Patients With Lung Cancer. A. KASPRZYK, K. BILMIN, T. CHMIELEWSKA-IGNATOWICZ, J. PAWLIKOWSKI, U. RELIGIONI, P. MERKS (Warsaw; Lublin; Bydgoszcz, Poland) ........................................................................................................ 53

PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance. E. VOUTYRITSA, C. DAMASKOS, P. FARMAKI, G. KYRIAKOS, E. DIAMANTIS, L.V. QUILES-SANCHEZ, A. GARMPI, N. GARMPI, A. PATSOURAS, A. STELIANIDI, S. SAVVANIS (Athens; Piraeus, Greece; Cartagena; Murcia, Spain) ........................................................................................................ 61

Contents continued on the back cover
Editorial Board

I. ABRAHAM, Tucson, AZ, USA
N. J. AGNANTIS, Ioannina, Greece
D. ANDERSON, Bradford, West Yorkshire, UK
V. BARAK, Jerusalem, Israel
M. H. BARCELLOS-HOFF, New York, NY, USA
K. BEIER, Basel, Switzerland
M. BERGOVIST,Upsala, Sweden
R. BJERKVIG, Bergen, Norway
W. BOWNE, Philadelphia, PA, USA
M. CARAGLIA, Naples, Italy
P. CHANDRA, Frankfurt am Main, Germany
J.-G. CHUNG, Taichung, Taiwan, ROC
L. A. COHEN, Northampton, MA, USA
A. I. CONSTANTINOU, Nicosia, Cyprus
T. DALIANS, Stockholm, Sweden
D. T. DENHARDT, Bridgewater, NJ, USA
W. DEN OTTER, Amsterdam, The Netherlands
K. DE MEIRLER, Brussels, Belgium
L. DE RIDDER, Ghent, Belgium
E. P. DIAMANDIS, Toronto, ON, Canada
J. M. DRAKE, New Brunswick, NJ, USA
T. EFFERTH, Mainz, Germany
W. ENGSTROM, Upsala, Sweden
M. ESKELENIEN, Kuopio, Finland
J. A. FERNANDEZ-POL, Chesterfield, MO, USA
G. FIORENTINI, Pesaro, Italy
P. B. FISHER, New York, NY, USA
I. FREITAS, Pavia, Italy
M. FRIEDRICH, Krefeld, Germany
R. E. FRIEDRICH, Hamburg, Germany
R. GASAPATHI, Charlotte, NC, USA
V. GORGOLIS, Athens, Greece
J. S. GRESNER, Pittsburgh, PA, USA
J. W. GREINER, Bethesda, MD, USA
C. J. GRUBBS, Birmingham, AL, USA
F. GUADAGNI, Rome, Italy
J. HAU, Copenhagen, Denmark
M. HAUER-JENSEN, Little Rock, AR, USA
K. S. JEONG, Daegu, S. Korea
M. HANWARR-UNYAL, Valhalla, NY, USA
I. KISS, Pécs, Hungary
M. KOUTSILIERIS, Athens, Greece
G. R. F. KRUEGER, Köln, Germany
N. KYPRIANOU, Lexington, KY, USA
G. LANDBERG, Lund, Sweden
J. LEROY, Strasbourg, France
W. LICHTENEGGER, Berlin, Germany
J. LYKESFELDT, Frederiksdal, Denmark

P. MADARNAS, Sherbrooke, QC, Canada
H. MAEDA, Kumamoto, Japan
M. MAREL, Ghent, Belgium
L. MARGOLIS, Bethesda, MD, USA
G. MARTORANA, Bologna, Italy
J. MOLNÁR, Szeged, Hungary
S. L. MOOBERRY, San Antonio, TX, USA
N. MOTOHASHI, Tokyo, Japan
R. M. NAGLER, Hadera, Israel
S. NAKANO, Fukushima, Japan
M. NAKASHIMA, Nagasaki, Japan
M. B. NICOLL, San Antonio, TX, USA
K. NILSSON, Upsala, Sweden
K. R. NORUM, Oslo, Norway
K. OGAWA, Tokyo, Japan
M. PÁGE, Laval, QC, Canada
C. POLYCHRONAKOS, Montreal, QC, Canada
M.-F. POUPON, Paris, France
D. RADES, Liibekk, Germany
F. M. ROBERTSON, Richmond, VA, USA
D. RUBELLO, Rovigo, Italy
C. A. RUBIO, Stockholm, Sweden
G. R. RUTTENMA, Utrecht, The Netherlands
H. SAKAGAMI, Saitama, Japan
G. SAVA, Trieste, Italy
D. SCHIEFFER, Veracelli, Italy
L. D. SHULTZ, Bar Harbor, ME, USA
G. SICA, Rome, Italy
J. SIEGFRIED, Minneapolis, MN, USA
J. SLANSKY, Denver, CO, USA
R. M. SNAPKA, Columbus, OH, USA
G.-I. SOMA, Kagawa, Japan
P. P. SORDILLO, New York, NY, USA
T. A. SPRINGER, Boston, MA, USA
D. D. SPIROPOULOS, Charleston, SC, USA
K. SYRJÄNEN, Helsinki, Finland
G. C. TORRE, Firenze Ligure (SV), Italy
T. TRIBUKAIT, Stockholm, Sweden
J. VADGAMA, Los Angeles, CA, USA
J.K. VISHWANATH, Fort Worth, TX, USA
W. WANG, Wolverhampton, UK
N. WATANABE, Sapporo, Japan
W. WEBER, Basel, Switzerland
L. M. WEINER, Washington, DC, USA
J. A. WERNER, Marburg, Germany
S. YLÄ-HERTTULAA, Kuopio, Finland
H. YOSHIDA, Kagoshima, Japan

G. J. DELINASIOS, Athens, Greece
Managing Editor and Executive Publisher
Editorial Office: journals@iiar-anticancer.org
Managing Editor: editor@iiar-anticancer.org
For more information about IN VIVO, IAR and the International Conferences of Anticancer Research, please visit the IAR website: www.iiar-anticancer.org

J. G. DELINASIOS, Athens, Greece
Managing Editor and Executive Publisher (1987-2016)

Copyright © 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
Editorial Board

I. ABRAHAM, The HOPE Center, University of Arizona, Tucson, AZ, USA
N.J. AGNANTIS, Department of Pathology, University of Ioannina, Ioannina, Greece
D. ANDERSON, Department of Biomedical Sciences, University of Bradford, Bradford, West Yorkshire, UK
V. BARAK, Department of Oncology, Hadassah University Hospital, Jerusalem, Israel
M.H. BARCELLOS-HOFF, Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA
K. BEIER, Department of Histology, University of Basel, Basel, Switzerland
M. BERGQVIST, Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden
R. BJERKVIG, Norlux Neuro-Oncology, Department of Biomedicine, University of Bergen, Bergen, Norway
W. BOWNE, Department of Surgery, Drexel University College of Medicine, Philadelphia, PA, USA
M. CARAGLIA, Department of Experimental Oncology, National Institute of Tumours Fondazione G. Pascale, Naples, Italy
P. CHANDRA, Department of Molecular Biology, Frankfurt University, Frankfurt am Main, Germany
J.-G. CHUNG, Department of Medicine, China Medical College, Taichung, Taiwan, ROC
L.A. COHEN, Northampton, MA, USA
A.I. CONSTANTINOU, Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus
T. DALIANIS, Department of Pathology-Oncology, Karolinska Institute, Stockholm, Sweden
D.T. DENHARDT, Division of Life Sciences, Rutgers University, Bridgewater, NJ, USA
W. DEN OTTER, VUMC - Department of Urology, Amsterdam, The Netherlands
K. DE MEIRLEIR, Department of Human Physiology and Medicine, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium
L. DE RIDDER, Department of Anatomy, Embryology and Histology, University of Ghent, Ghent, Belgium
E.P. DIAMANDIS, Department of Pathology and Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada
J.M. DRAKE, Division of Medical Oncology, RBHS-Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
T. EFFERTH, Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Germany
W. ENGSTRÖM, Department of Molecular Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden
M. ESKELINEN, Department of Surgery, University Hospital of Kuopio, Kuopio, Finland
J.A. FERNANDEZ-POL, Metalloproteomics, LLC, Chesterfield, MO, USA
G. FIORENTINI, UOC Oncologia, Azienda Ospedaliera Marche Nord, Pesaro, Italy
P.B. FISHER, Virginia Commonwealth University, School of Medicine, Richmond, VA, USA
I. FREITAS, Dipartimento di Biologia Animale, University of Pavia, Pavia, Italy
M. FRIEDRICH, Department of Obstetrics and Gynecology, Klinikum Krefeld, Krefeld, Germany
R.E. FRIEDRICH, Department of Oral and Maxillofacial Surgery, Eppendorf University Hospital, Hamburg, Germany
R. GANAPATHI, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
V. GORGOLIS, Department of Histology-Embryology, Medical School, University of Athens, Greece
J.S. GREENBERGER, Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA
J.W. GREINER, National Cancer Institute, NIH, Bethesda, MD, USA
D.S. GRIDLEY, Department of Radiation Medicine, Radiation Research Laboratories, Loma Linda University and Medical Center, Loma Linda, CA, USA
C.J. GRUBBS, Department of Nutrition Sciences, University of Alabama, Birmingham, AL, USA
F. GUADAGNI, IRCCS San Raffaele, Rome, Italy
J. HAU, Department of Comparative Medicine, University of Copenhagen, Denmark
Acknowledgements

The following Organisations supported many of the works published in IN VIVO, Volume 34, 2020.

Adaptable and Seamless Technology Transfer Program (A-Step), Ministry of Education, Culture, Sports, Science and Technology of Japan, Tokyo, Japan
Akershus University Hospital, Nordbyhagen, Norway
Asahi University, Mizuho, Japan
Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea
Asia University, Taichung, Taiwan, R.O.C.
Aklepios Klinik Altona, Hamburg, Germany
Association of Healthcare Corporation, Japan
Athens Genesis Clinic, Athens, Greece
Augustinus Foundation, Copenhagen, Denmark
Baden-Württemberg Ministry of Science, Research and the Arts, Germany
Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
Bio & Medical Technology Development Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
Biobank of Korea University Guro Hospital, Seoul, Republic of Korea
Bremer Cancer Society, Bremer, Germany
Cancer Center, Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.
Cancer Society of Finland, Helsinki, Finland
Cathay General Hospital, Taipei, Taiwan, R.O.C.
Center for Drug Delivery Research, Tokyo University of Science, Tokyo, Japan
Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.
Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.
Changhua Christian Hospital, Changhua, Taiwan, R.O.C.
Charles University Research Fund (PROGRES), Charles University in Prague, Prague, Czech Republic
Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C.
China Medical University Hospital, Taichung, Taiwan, R.O.C.
China Scholarship Council, Beijing, P.R. China
Chonnam National University Hospital, Gwangju, Republic of Korea
Chosun University Hospital Clinical Medicine Research Institute, Gwangju, Republic of Korea
Chosun University, Gwangju, Republic of Korea
Chungnam National University Hospital Research Fund, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
Chungnam National University, Daejeon, Republic of Korea
Clinical Research Center, Dokkyo Medical University School of Medicine, Mibu, Japan
Collaborative Genome Program for Fostering New Post-Genome Industry, National Research Foundation (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
Comenius University, Bratislava, Slovak Republic
Conceptual Development of Research Organization, Faculty Hospital in Pilsen - FNPI, Pilsen, Czech Republic
Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brasilia, Brazil
Cooperative Research Program for Agriculture Science and Technology Development, Rural Development Administration, Republic of Korea
Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, R.O.C.
Dental Research Center, Nihon University School of Dentistry, Tokyo, Japan
Department of General Surgical Science, Gunma University, Maebashi, Japan
Department of Head and Neck Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Department of Histology and Embryology of Wroclaw Medical University, Wroclaw, Poland
Department of Molecular Diagnostic Pathology, Dokkyo Medical University School of Medicine, Mibu, Japan
Department of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Matsuyama, Japan
Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
Department of Otorhinolaryngology, China Medical University Hospital, Taichung, Taiwan, R.O.C.
Department of Otorhinolaryngology, Eppendorf University Hospital, Hamburg, Germany
Department of Pathology, Faculty of Medicine, Prince of Songkla University (PSU), Hat Yai, Thailand
Department of Pathology, Hanyang University Hospital, Seoul, Republic of Korea
Department of Pathology, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland
Department of the Human Anatomy Centre, University of Rome La Sapienza, Rome, Italy
Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
Department of Urology, Saiseikai Kurihashi Hospital, Kuki, Japan
Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan
Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany
Division of Clinical Laboratory and Clinical Application, Nanpuk Hospital, Kagoshima, Japan
Elena Venizelou Hospital, Athens, Greece
ELPEN Pharma, Pikermi, Greece
Eulji University, Daejeon, Republic of Korea
EURAXESS, European Commission, Europe
European Regional Development Fund (ERDF), Brussels, Belgium
European Research Council
European Social Fund (ESF), European Commission, Brussels, Belgium
European Union
Evangelismos Hospital, Athens, Greece
Ewha Womans University Research Grant, Seoul, Republic of Korea
Experimental, Educational and Research Center, ELPEN, Pikermi, Greece
Faculty of Science of Tunisia, Tunisia
Faxitron Bioptics, LLC, Tucson, AZ, U.S.A.
Featured Areas Research Center Program, Higher Education Sprout Project, Ministry of Education (MOE), Taiwan, R.O.C.
Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany
Frontier Research Center, Taiwan, R.O.C.
Fuji Micra Inc., Fujinomiya, Japan
Fukuoka Wajiro Hospital, Fukuoka, Japan
Fundação para a Ciência e a Tecnologia (FCT), Ministério da Ciência e Ensino Superior, Portugal
Funduo Europeu de Desenvolvimento Regional (FEDER), Lisbon, Portugal
Gachon University Gil Medical Center, Incheon, Republic of Korea
General University Hospital in Prague, Prague, Czech Republic
German Cancer Society, Germany
Granada University, Granada, Spain
Grant-in Aid from the Japanese Ministry of Education, Science, Sports and Culture of Japan, Tokyo, Japan
Grants-in-Aid for Scientific Research (KAKENHI), Japan Society for the Promotion of Science, Tokyo, Japan
Hallym University Research Fund, Chuncheon, Republic of Korea
Head and Neck department of Surgery, Metaxa Anti-Cancer Hospital, Piraeus, Greece
Health Labor Sciences Research Grant, Ministry of Health, Labor and Welfare of Japan, Japan
Health Research Fund of Central Denmark Region, Denmark
Higher Education Sprout Project, Ministry of Education, Taipei, Taiwan, R.O.C.
Hillman Animal Research Core Facility, University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, PA, U.S.A.
Hiroshima Prefecture Government, Japan
Hitachi, Ltd, Tokyo, Japan
Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic
Hospital Chomutov, Chomutov, Czech Republic
Hospital Na Bulovce, Prague, Czech Republic
Hospital Na Homolce, Prague, Czech Republic
Hospital Novy Jicin, Novy Jicin, Czech Republic
Hospital Pardubice, Prague, Czech Republic
Hyogo College of Medicine, Nishinomiya, Japan
Hyogo Innovative Challenge, Hyogo College of Medicine, Nishinomiya, Japan
Institut de la Santé et la Recherche Médicale (INSERM), Paris, France
Institute for Medical Biometry and Epidemiology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
Institute of Cancer Research, London, U.K.
Institute of Polish Mother’s Memorial Hospital, Lodz, Poland
Institute of Polish Mother’s Health Center, Lodz, Poland
Interreg Deutschland-Danmark, Kiel, Germany
Italian Ministry of Health, Rome, Italy
Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania
János Bolyai Research Scholarship, Hungarian Academy of Sciences, Hungary
Japan Agency for Medical Research and Development (AMED), Tokyo, Japan
Japanese Center for AntiAging MedSciences, Japan
Japanese Ministry of Health, Japan
Japanese Society of Internal Medicine, Japan
Japanese Society of Surgery, Japan
Joint Committee of University Cooperation PHC Utique, France/Tunisia
J-Pharma Co., Ltd., Yokohama, Japan
Kawaguchi Institute of Periodontology and Implantology, Kawaguchi, Japan
Kawasaki Medical School, Kurashiki, Japan
Knud and Edith Eriksens Memorial Foundation, Denmark
Instructions for Authors 2021

**General Policy.** IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis; Each article should include a concrete conclusion constituting of a “new piece of knowledge” backed up by scientific evidence. 10. Retrospective studies and case reports. The principal aim of IN VIVO is to provide for the prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to peer-review, when appropriate, by two members of the Editorial Board. All manuscripts submitted to IN VIVO are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

**Open Access Policy.** IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 800.00 (effective January 1, 2021) for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 60.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume and issue numbers, as well as page numbering.

**Copyright.** Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of IN VIVO articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in IN VIVO are the property of the publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Conflicts of Interest; (h) Authors’ contributions; (i) Acknowledgements; (j) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are not subject to color charges.

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “NCT”). Please note that there is no space between the prefix “NCT” and the number. Example: NCT00001789.

Ethical Policies and Standards. IN VIVO agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. In Vivo (IV) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfills the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.
3. Each manuscript submitted to IV is sent for peer-review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to IV, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

4. All accepted manuscripts are carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

5. Authors should pay attention to the following points when writing an article for IN VIVO:
   • The Instructions to Authors must be followed in every detail.
   • The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   • The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   • Results given in figures should not be repeated in tables.
   • Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   • Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   • Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   • Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   • Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by… authors, year).
   • References. Each article should address, list and discuss the entire spectrum of current publications relevant to its field.
   • By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

8. Articles submitted to IN VIVO may be rejected without review if:
   • they do not fall within the journal’s policy.
   • they do not follow the instructions for authors.
   • language is unclear.
   • results are not sufficient to support a final conclusion.
   • results are not objectively based on valid experiments.
   • they repeat results already published by the same or other authors before the submission to IV.
   • plagiarism is detected by plagiarism screening services.
   (Rejection rate (2020): 64%).

9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org.

11. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
   (This text is a combination of advice and suggestions contributed by Editors, Authors and the Managing Editor of IV).

Copyright © 2021 – International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.